Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2016

View Archived Issues

Nano Dimension and Accellta print viable stem cells using adapted 3D printer

PositiveID detects Zika virus on Firefly Dx prototype system

Spero Therapeutics signs research agreement with Vertex Pharmaceuticals

National University of Singapore researchers design technology to make customizable pills

Symbiomix reports clinical results for SYM-1219

Boehringer Ingelheim Pharma patents somatostatin receptor agonists

Lilly discloses Aurora kinase A inhibitors

Nerviano Medical Sciences reports Ret inhibitors

GlaxoSmithKline divulges TLR7 agonists

Quretech introduces antibacterial compounds

FDA grants new QIDP designation to MBN-101

TMEM126B mutations cause severe isolated complex I deficiency with variable clinical phenotype

Flexion Therapeutics receives FDA response to questions on FX-006

CSL gains FDA approval for lonoctocog alpha

ProNAi Therapeutics obtains license to AS-141 from Carna Biosciences

Cellceutix updates phase II Prurisol results

EMA committee recommends approval of Revestive for pediatric patients with short bowel syndrome

Caladrius licenses technology to AiVita Biomedical

Novel biomarker genes associated with intellectual disability

Minerva Neurosciences presents topline results for MIN-117 and MIN-101

Cancer Research Technology and Pangaea sign license agreement for PAK inhibitor drugs

NIH funds biobank at Mayo Clinic as part of PMI Cohort Program

FDA approves Probuphine for opioid dependence

P2Y6 receptor shows potential as a therapeutic target for the treatment of asthma

FDA awards fast track designation to Indivior's RBP-6000 buprenorphine monthly depot

Clinical remissions seen with risankizumab in phase II Crohn's disease study

FDA issues complete response letter for sodium zirconium cyclosilicate for hyperkalemia

FDA approves Fanapt sNDA for maintenance treatment of schizophrenia in adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...